{
  "alleleExist":false,
  "dataVersion":"v4.5",
  "diagnosticImplications":[],
  "diagnosticSummary":"",
  "geneExist":true,
  "geneSummary":"PLCG2 encodes an enzyme involved in transmembrane signaling. Mutations of PLCG2 are associated with autoimmunity and immune dysregulation and resistance to Ibrutinib therapy in patients with CLL.",
  "highestDiagnosticImplicationLevel":null,
  "highestFdaLevel":null,
  "highestPrognosticImplicationLevel":null,
  "highestResistanceLevel":null,
  "highestSensitiveLevel":null,
  "hotspot":false,
  "lastUpdate":"01/17/2017",
  "mutationEffect":{
    "citations":{
      "abstracts":[],
      "pmids":[]
    },
    "description":"",
    "knownEffect":"Unknown"
  },
  "oncogenic":"Unknown",
  "otherSignificantResistanceLevels":[],
  "otherSignificantSensitiveLevels":[],
  "prognosticImplications":[],
  "prognosticSummary":"",
  "query":{
    "alteration":"L230fs",
    "alterationType":null,
    "consequence":"frameshift_variant",
    "entrezGeneId":5336,
    "hgvs":"16:g.81880951del",
    "hugoSymbol":"PLCG2",
    "id":null,
    "proteinEnd":230,
    "proteinStart":230,
    "referenceGenome":"GRCh38",
    "svType":null,
    "tumorType":null
  },
  "treatments":[],
  "tumorTypeSummary":"",
  "variantExist":false,
  "variantSummary":"The biologic significance of the PLCG2 L230fs mutation is unknown.",
  "vus":false
}